Pay in 4 interest-free payments of $6.19 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Clinical Stroke Trials Human clinical trials have yielded inconsistent results regarding efficacy: CARS trial (n=208): Demonstrated beneficial effects on global function and motor recovery in early rehabilitation patients[9] CASTA trial (n=1,070): Failed to show benefit over placebo in primary composite outcomes in Asian stroke patients[10] Meta-analyses suggest possible benefits in patients with severe stroke, but limited effects in mild-to-moderate cases[11] Safety profile comparable to placebo in most studies Neurodegenerative Disease Research Alzheimers Disease Models Research in transgenic mouse models of Alzheimers disease demonstrated effects on amyloid pathology and cognitive function[12]: Reduced amyloid plaque burden in APP transgenic mice Improved behavioral performance in memory tasks Decreased amyloid precursor protein maturation Effects maintained for 3 months after treatment discontinuation Vascular Dementia Studies Clinical investigations in vascular dementia patients showed more consistent positive findings[13]: Improved ADAS-cog cognitive scores (10.6-point improvement vs 4.4 points placebo) Enhanced global clinical function ratings (CIBIC+ scores) Benefits observed in 24-week treatment protocols with intravenous administration Effects demonstrated in multiple randomized controlled trials Traumatic Brain Injury Research Experimental TBI Models Studies in rat models of mild-to-moderate traumatic brain injury revealed dose-dependent functional improvements[14]: Enhanced long-term cognitive recovery at doses of 0.8-7.5 ml/kg Optimal dose identified as 2.5 ml/kg in closed head injury models Reduced astrogliosis and axonal injury markers Improved neurogenesis in dentate gyrus region Excitotoxicity Protection Research using kainic acid lesion models demonstrated neuroprotective effects[15]: Significant protection when administered before excitotoxic challenge Limited benefit when given after injury (therapeutic window considerations) Enhanced neuronal structure preservation in hippocampus Improved water maze performance in protected animals Critical Research Limitation: Clinical trial results for Cerebrolysin have been notably inconsistent
Acetyl-L-carnitine to enhance nerve regeneration in carpal tunnel syndrome: a double-blind, randomized, controlled trial
The Two Versions Explained CJC-1295 with DAC (Drug Affinity Complex) Extended half-life (6-8 days) Less frequent dosing required Provides continuous GH elevation Causes GH "bleed" rather than pulse CJC-1295 without DAC (Mod GRF 1-29) Short half-life (30 minutes) Requires multiple daily doses Mimics natural GH pulsatile release More physiological approach Key Differences Comparison Which Should You Choose
It is not a drug, food, or cosmetic and is not for human or animal consumption
Ships across Canada with fast delivery and pickup options
